Clinical Trial Update: A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) [Phase 1]

View source ↗

Summary

A Phase 1 study (THUNDERBBOLT-1) evaluating ERAS-801 in recurrent glioblastoma is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• ERAS-801

Snippet

Sponsor: Katmai Pharmaceuticals Inc. | Conditions: Glioblastoma Multiforme | Phase 1 | Status: ACTIVE_NOT_RECRUITING